ONCOLOGY Vol 36, Issue 1 | Oncology

February 07, 2022

ONCOLOGY co-editor-in-chief Julie M. Vose, MD, MBA, anticipates how COVID-19 will continue to impact the oncology field.

January 20, 2022

This review article discusses which frontline treatment are best for diffuse large B-cell lymphoma.

January 20, 2022

Patients 70 years or older that received neoadjuvant chemotherapy and radical cystectomy had better overall survival than those undergoing radical cystectomy alone.

January 20, 2022

Jun Gong, MD, gives his perspective on neoadjuvant chemotherapy in elderly patients with muscle-invasive bladder cancer.

January 19, 2022

Although female representation for National Comprehensive Cancer Network guidelines has increased to at least 50%, participation in guideline panels across all organizations is still less than 30%.

January 18, 2022

“If we can understand the mechanisms of resistance to be able to monitor [patients] in real time, then we will be able to turn many cases of cancer into chronic diseases.”

January 18, 2022

In an interview with ONCOLOGY®, Natasha Khrystolubova, BPharm, RPh, BCOP, offers a comprehensive review of real-world treatment considerations of belzutifan as therapy for patients with renal cell carcinoma.

January 14, 2022

This issues Publisher's Note focuses on a manuscript regarding gender equity on oncology guideline panels.